GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) » Definitions » EPS without NRI

Biohaven Pharmaceutical Holding Co (Biohaven Pharmaceutical Holding Co) EPS without NRI : $-14.82 (TTM As of Jun. 2022)


View and export this data going back to 2017. Start your Free Trial

What is Biohaven Pharmaceutical Holding Co EPS without NRI?

Biohaven Pharmaceutical Holding Co's earnings per share without non-recurring items for the three months ended in Jun. 2022 was $-6.21. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2022 was $-14.82.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -28.60% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -28.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Biohaven Pharmaceutical Holding Co's EPS without NRI or its related term are showing as below:

BHVN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0   Med: -36.1   Max: -28.6
Current: -28.6

During the past 7 years, Biohaven Pharmaceutical Holding Co's highest 3-Year average Earnings Per Share (NRI) Growth Rate was -28.60% per year. The lowest was 0.00% per year. And the median was -36.10% per year.

BHVN's 3-Year EPS without NRI Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 4.7 vs BHVN: -28.60

Biohaven Pharmaceutical Holding Co's EPS (Diluted) for the three months ended in Jun. 2022 was $-6.21. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $-14.82.

Biohaven Pharmaceutical Holding Co's EPS (Basic) for the three months ended in Jun. 2022 was $-6.21. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2022 was $-14.82.


Biohaven Pharmaceutical Holding Co EPS without NRI Historical Data

The historical data trend for Biohaven Pharmaceutical Holding Co's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Pharmaceutical Holding Co EPS without NRI Chart

Biohaven Pharmaceutical Holding Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EPS without NRI
Get a 7-Day Free Trial -5.00 -6.15 -10.91 -13.06 -13.09

Biohaven Pharmaceutical Holding Co Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.23 -2.63 -3.01 -2.97 -6.21

Competitive Comparison of Biohaven Pharmaceutical Holding Co's EPS without NRI

For the Biotechnology subindustry, Biohaven Pharmaceutical Holding Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biohaven Pharmaceutical Holding Co's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biohaven Pharmaceutical Holding Co's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Biohaven Pharmaceutical Holding Co's PE Ratio without NRI falls into.



Biohaven Pharmaceutical Holding Co EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biohaven Pharmaceutical Holding Co  (NYSE:BHVN) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Biohaven Pharmaceutical Holding Co EPS without NRI Related Terms

Thank you for viewing the detailed overview of Biohaven Pharmaceutical Holding Co's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Biohaven Pharmaceutical Holding Co (Biohaven Pharmaceutical Holding Co) Business Description

Traded in Other Exchanges
N/A
Address
C/o Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, CT, USA, 06510
Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV-3100, BHV5000, BHV5500, among others.
Executives
Gregory Bailey director 4 A CHESHAM STREET, LONDON X0 SW1X8DT
George C. Clark officer: VP, Chief Accounting Officer 215 CHURCH STREET, NEW HAVEN CT 06510
Irina Antonijevic director 215 CHURCH STREET, NEW HAVEN CT 06510
Julia P Gregory director 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Elyse Stock officer: Chief Medical Officer 215 CHURCH STREET NEW HAVEN CT 06510
James Engelhart officer: Chief Financial Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Matthew Buten officer: Officer 215 CHURCH STREET, NEW HAVEN CT 06510
Declan Doogan director C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
John W Childs director, 10 percent owner 111 HUNTINGTON AVENUE, SUITE 2900, BOSTON MA 02199
Kishan Mehta director 540 WEST 49TH STREET, UNIT# PH1N, NEW YORK NY 10019
Jones William A Jr officer: CCO-Migraine & Common Disease NITROMED, INC., 125 SPRING STREET, LEXINGTON MA 02421
Kimberly Gentile officer: VP of Operations C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Robert Berman officer: Chief Medical Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
John Tilton officer: Chief Commercial Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Robert J Hugin director C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054